Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon LtdfiledCriticalBiocon Ltd
Priority to MYPI2019002430ApriorityCriticalpatent/MY191211A/en
Publication of MY191211ApublicationCriticalpatent/MY191211A/en
The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells. (Figure 29)
MYPI2019002430A2013-03-132013-03-13Targeted/immunomodulatory fusion proteins and methods for making same
MY191211A
(en)
Compositions and formulations for prevention and reduction of tumorigenesis, cancer cell proliferation and invasion, and methods of production and use thereof in cancer treatment.